NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
05/22/2026
Back to search
Official data from USPTO
SYMPROIC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
05/23/2026
Trademark type
Combined
Nice classes
5
Filing date
01/27/2015
Registration date
01/19/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/22/2026
Last transaction
05/23/2026
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
5
Owner type
03
Owner location
Osaka-shi, Osaka, JP
Examiner
HUSSAIN, TASNEEM
Current location
Historical data usage
Mark description
The mark consists of the stylized wording "SYMPROIC".
Holders and representatives
Holders
SHIONOGI & CO., LTD.
SHIONOGI & CO., LTD.
Representatives
Mainak H. Mehta Procopio, Cory, Hargreaves & Savitch LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment and prevention of cardiovascular diseasesdiabetesobesitycancerendocrine disordershormonal diseases and disordersurological disorderssexual dysfunctionHIV and AIDscentral nervous systems diseases and disordersperipheral nervous system diseases and disordersosteoporosisrheumatismneurological disorderspaingastrointestinal disordersrespiratory diseases and disordersallergiesbacterial disordersviral disordersfungal disordersinfectious diseasesinflammation and inflammatory diseasessepsisimmunological disordersmusculoskeletal disordersdisease and disorders of the liverallergic rhinitisthrombocytopenia; pharmaceutical preparations for treating opioid-induced constipation
Publications
History of USPTO decisions and trademark events.
33 publications found
71AG
REGISTERED-SEC.71 ACCEPTED
05/22/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/18/2026
ES71
TEAS SECTION 71 RECEIVED
01/26/2026
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
01/19/2025
RNWL
INTERNATIONAL REGISTRATION RENEWED
12/19/2024
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
05/24/2022
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
05/24/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/23/2022
ES75
TEAS SECTION 71 & 15 RECEIVED
11/11/2021
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
05/13/2016
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/22/2016
FIMP
FINAL DISPOSITION PROCESSED
04/22/2016
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/19/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
01/19/2016
PUBO
PUBLISHED FOR OPPOSITION
11/03/2015
NPUB
NOTICE OF PUBLICATION
10/14/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/29/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/29/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/24/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/24/2015
ALIE
ASSIGNED TO LIE
09/17/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/01/2015
RFNT
REFUSAL PROCESSED BY IB
08/01/2015
MAFR
APPLICATION FILING RECEIPT MAILED
07/11/2015
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/10/2015
RFRR
REFUSAL PROCESSED BY MPU
07/10/2015
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/09/2015
CNRT
NON-FINAL ACTION WRITTEN
07/08/2015
DOCK
ASSIGNED TO EXAMINER
07/07/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/07/2015
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
07/06/2015
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/02/2015
Continuous trademark protection
Get notified about every new filing that threatens SYMPROIC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.